Sinocelltech’s Herpes Zoster Vaccine SCTV04C Clears NMPA for Clinical Trial

Sinocelltech Group Ltd (SHA: 688520), a biopharmaceutical company based in China, has received approval from the National Medical Products Administration (NMPA) to commence clinical trials for SCTV04C, its proprietary recombinant herpes zoster vaccine. Herpes zoster, commonly known as shingles, is an infectious skin condition that results from the reactivation of the dormant varicella zoster virus (VZV). The upcoming clinical study will evaluate the efficacy of SCTV04C in preventing herpes zoster and associated complications in healthy adult populations due to VZV infection.- Flcube.com